Developer docs
API playgroundTry for free, no card

Search company profiles

Apnimed

Full company profile

uuid00004k8

Namestring
Apnimed
Legal namestring
Apnimed, Inc.
Websiteurl
apnimed.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Apnimed is a late-stage clinical pharmaceutical company founded in 2017 and headquartered in Cambridge, Massachusetts, dedicated to developing oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep-related breathing disorders. The company's lead product candidate, AD109, is a first-in-class fixed-dose oral combination of aroxybutynin (a novel anti-muscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) designed to be taken once daily at bedtime. Unlike existing mechanical interventions such as CPAP, AD109 targets the underlying neuromuscular dysfunction of OSA by improving upper airway muscle tone during sleep, with the goal of maintaining airway patency. The drug has completed two Phase 3 trials (SynAIRgy and LunAIRo) enrolling over 1,300 participants, achieving statistically significant reductions in the apnea-hypopnea index of 55.6% and 46.8% respectively, and an NDA has been submitted to the FDA with a PDUFA target action date expected in Q1 2027.

The company has no current commercial revenue and operates as a pre-launch organization funded by venture capital and a recent $150 million debt facility from HealthCare Royalty Partners. Apnimed has assembled a senior leadership team with deep pharmaceutical commercialization experience — including a CEO (Kevin Lind) who previously led Longboard Pharmaceuticals through its acquisition by Lundbeck for $2.6 billion, and a Chief Commercial Officer who led the Nurtec ODT launch at Biohaven prior to its $11.6 billion acquisition by Pfizer. The firm is building a traditional US pharmaceutical go-to-market infrastructure including field-based Medical Science Liaisons, medical affairs, and commercial analytics functions, targeting an addressable market of 80+ million US adults and approximately 1 billion people worldwide suffering from OSA. In March 2026, Apnimed divested its 50% stake in the Shionogi-Apnimed Sleep Science joint venture for $100 million upfront plus a $50 million milestone, refocusing the company exclusively on its wholly-owned AD109 program ahead of the expected commercial launch.

Short descriptiontext

Apnimed is a Cambridge, MA-based late-stage clinical pharmaceutical company developing AD109, a first-in-class once-daily oral combination therapy for obstructive sleep apnea, with an NDA submitted to the FDA and a PDUFA target date in Q1 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obstructive sleep apnea therapy, oral pharmacologic treatment, sleep-related breathing disease, neuromuscular modulator drug, clinical-stage pharmaceutical
Industry3 codes
PRIMARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAKANAB
Sleep Medicine Clinic
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sleep Apnea Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Once AD109 receives FDA approval, Apnimed plans to generate revenue through the sale of prescription pharmaceutical products. The company is preparing for US commercial launch with a field-based medical affairs team and commercial infrastructure.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Apnimed is a clinical-stage pharmaceutical company developing novel oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep-related breathing diseases. Its lead product candidate AD109 is a first-in-class fixed-dose combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) administered as a once-daily bedtime pill. The drug targets the underlying neuromuscular dysfunction in OSA to improve upper airway muscle activity and maintain airway patency during sleep, representing what the company positions as a potential first oral pharmacological treatment for OSA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 55.6% reduction in AHI (apnea-hypopnea index) from baseline at 26 weeks in SynAIRgy trial
+5 more records
Product overview1 text field

Apnimed is a late-stage clinical pharmaceutical company developing novel oral therapies for sleep-related breathing diseases. The company's primary focus is AD109, an investigational oral pill for obstructive sleep apnea (OSA) combining aroxybutynin and atomoxetine. Apnimed has completed two Phase 3 clinical trials (SynAIRgy and LunAIRo) and has submitted its New Drug Application to the FDA, with a potential PDUFA target action date expected in Q1 2027.

Product and service1 record
1AD109
CategorySleep apnea prescription pharmaceutical
Description

AD109 is an investigational, first-in-class, fixed-dose oral combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor). It is designed to improve oxygenation during sleep by targeting the neuromuscular root cause of obstructive sleep apnea, administered as a once-daily pill taken at bedtime for adults with mild, moderate, or severe OSA.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Strategic monetization of Shionogi-Apnimed Sleep Science (SASS) joint venture where Shionogi acquired Apnimed's 50% ownership stake. Apnimed received $100 million upfront and a $50 million development milestone payment tied to SASS-002 (sulthiame), plus tiered royalties on future commercial sales. This allows Apnimed to focus on its wholly-owned OSA program AD109.

2Alliance of Sleep Apnea Partners (ASAP)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy partnership promoting and advocating for screening, diagnosis, treatment, and management of optimal health for those who suffer from sleep apnea.

apnimed.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Medical association partnership advancing sleep care and enhancing sleep health through advocacy, accreditation, membership, standards, and education.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy partnership advocating for people with sleep apnea and providing comprehensive educational resources on sleep apnea and treatment options.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy partnership dedicated to improving health and well-being through sleep education and advocacy.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy partnership dedicated to educating the public about sleep health, sleep equity, and sleep disorders through campaigns, events, and programs including the Sleep Apnea Squad educational series.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in CPAP and other OSA treatment devices; the dominant incumbent in obstructive sleep apnea therapy that Apnimed's AD109 oral pill would directly compete against by offering an alternative to PAP therapy.

TypeBroad incumbent
Description

Major CPAP and sleep-respiratory device manufacturer through its Respironics business, and Apnimed's CMO John Cronin was formerly Philips Respironics' Chief Medical Officer. A primary entrenched competitor in OSA treatment that AD109 would seek to displace.

TypeDirect peer
Description

Developer of an FDA-approved implantable hypoglossal nerve stimulation system for OSA, directly competing with AD109 as an alternative to CPAP for patients who fail or refuse PAP therapy.

TypeDirect peer
Description

Japanese pharma company that now fully owns the SASS joint venture and is developing sulthiame, an oral carbonic anhydrase inhibitor for OSA; a direct competitor in oral OSA pharmacotherapy and Apnimed's former JV partner.

TypeEmerging player
Description

Specialty pharma focused on sleep and neurological disorders with franchises in narcolepsy (Xywav, Sunosi); comparable as a sleep-disorder-focused commercial-stage pharma peer targeting similar prescriber channels.

TypeEmerging player
Description

Sleep-disorder pharma with Lumryz (once-at-bedtime sodium oxybate) for narcolepsy; comparable as a recent commercial-stage sleep pharma peer navigating payer access and prescriber adoption in sleep medicine.

TypeBroad incumbent
Description

Major CPAP and nasal-interface manufacturer for OSA therapy; a broad incumbent in sleep apnea treatment whose device-based standard of care AD109 would seek to disrupt.

TypeEmerging player
Description

Developer of the Genio hypoglossal nerve stimulation system for OSA, an alternative-to-CPAP therapy that competes for the same patient population AD109 is targeting.

9Eisai
TypeBroad incumbent
Description

Large Japanese pharma with sleep medicine franchise including Dayvigo (lemborexant) for insomnia; comparable as a broader pharma incumbent operating in the sleep medicine prescriber space.

TypeBroad incumbent
Description

Global pharma with historical sleep/neurology franchises; comparable as a broad incumbent that has commercialized sleep-disorder therapies and competes for prescriber attention in sleep medicine.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apnimed

Sleep Apnea Therapeuticsapnimed.com

Apnimed is a Cambridge, MA-based late-stage clinical pharmaceutical company developing AD109, a first-in-class once-daily oral combination therapy for obstructive sleep apnea, with an NDA submitted to the FDA and a PDUFA target date in Q1 2027.

What Apnimed does

Apnimed is a late-stage clinical pharmaceutical company founded in 2017 and headquartered in Cambridge, Massachusetts, dedicated to developing oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep-related breathing disorders. The company's lead product candidate, AD109, is a first-in-class fixed-dose oral combination of aroxybutynin (a novel anti-muscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) designed to be taken once daily at bedtime. Unlike existing mechanical interventions such as CPAP, AD109 targets the underlying neuromuscular dysfunction of OSA by improving upper airway muscle tone during sleep, with the goal of maintaining airway patency. The drug has completed two Phase 3 trials (SynAIRgy and LunAIRo) enrolling over 1,300 participants, achieving statistically significant reductions in the apnea-hypopnea index of 55.6% and 46.8% respectively, and an NDA has been submitted to the FDA with a PDUFA target action date expected in Q1 2027.

The company has no current commercial revenue and operates as a pre-launch organization funded by venture capital and a recent $150 million debt facility from HealthCare Royalty Partners. Apnimed has assembled a senior leadership team with deep pharmaceutical commercialization experience — including a CEO (Kevin Lind) who previously led Longboard Pharmaceuticals through its acquisition by Lundbeck for $2.6 billion, and a Chief Commercial Officer who led the Nurtec ODT launch at Biohaven prior to its $11.6 billion acquisition by Pfizer. The firm is building a traditional US pharmaceutical go-to-market infrastructure including field-based Medical Science Liaisons, medical affairs, and commercial analytics functions, targeting an addressable market of 80+ million US adults and approximately 1 billion people worldwide suffering from OSA. In March 2026, Apnimed divested its 50% stake in the Shionogi-Apnimed Sleep Science joint venture for $100 million upfront plus a $50 million milestone, refocusing the company exclusively on its wholly-owned AD109 program ahead of the expected commercial launch.

Apnimed firmographics

Firmographics
Name
Apnimed
Legal name
Apnimed, Inc.
Website
https://apnimed.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Apnimed is a Cambridge, MA-based late-stage clinical pharmaceutical company developing AD109, a first-in-class once-daily oral combination therapy for obstructive sleep apnea, with an NDA submitted to the FDA and a PDUFA target date in Q1 2027.
Ownership category
akta.pro rank

Apnimed industry classification

Industry
Product category
Sleep Apnea Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAGAA
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAKANAB
Sleep Medicine Clinic

Keywords

  • Obstructive sleep apnea therapy
  • Oral pharmacologic treatment
  • Sleep-related breathing disease
  • Neuromuscular modulator drug
  • Clinical-stage pharmaceutical

Where Apnimed is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Apnimed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical product sales: Once AD109 receives FDA approval, Apnimed plans to generate revenue through the sale of prescription pharmaceutical products. The company is preparing for US commercial launch with a field-based medical affairs team and commercial infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Apnimed product offering

Product offering

Core offering

Apnimed is a clinical-stage pharmaceutical company developing novel oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep-related breathing diseases. Its lead product candidate AD109 is a first-in-class fixed-dose combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) administered as a once-daily bedtime pill. The drug targets the underlying neuromuscular dysfunction in OSA to improve upper airway muscle activity and maintain airway patency during sleep, representing what the company positions as a potential first oral pharmacological treatment for OSA.

Product overview

Apnimed is a late-stage clinical pharmaceutical company developing novel oral therapies for sleep-related breathing diseases. The company's primary focus is AD109, an investigational oral pill for obstructive sleep apnea (OSA) combining aroxybutynin and atomoxetine. Apnimed has completed two Phase 3 clinical trials (SynAIRgy and LunAIRo) and has submitted its New Drug Application to the FDA, with a potential PDUFA target action date expected in Q1 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • AD109 AD109 is an investigational, first-in-class, fixed-dose oral combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor). It is designed to improve oxygenation during sleep by targeting the neuromuscular root cause of obstructive sleep apnea, administered as a once-daily pill taken at bedtime for adults with mild, moderate, or severe OSA.

Quantifiable outcome

  • 55.6% reduction in AHI (apnea-hypopnea index) from baseline at 26 weeks in SynAIRgy trial
  • +5 more outcomes

Companies that use Apnimed

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Apnimed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Apnimed partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and minor.

  • Shionogi & Co. LtdmajorStrategic or Co-development Partner · 24 March 2026Strategic monetization of Shionogi-Apnimed Sleep Science (SASS) joint venture where Shionogi acquired Apnimed's 50% ownership stake. Apnimed received $100 million upfront and a $50 million development milestone payment tied to SASS-002 (sulthiame), plus tiered royalties on future commercial sales. This allows Apnimed to focus on its wholly-owned OSA program AD109.
  • Alliance of Sleep Apnea Partners (ASAP)minorGTM or Marketing PartnerPatient advocacy partnership promoting and advocating for screening, diagnosis, treatment, and management of optimal health for those who suffer from sleep apnea.
  • American Academy of Sleep Medicine (AASM)minorGTM or Marketing PartnerMedical association partnership advancing sleep care and enhancing sleep health through advocacy, accreditation, membership, standards, and education.
  • American Sleep Apnea Association (ASAA)minorGTM or Marketing PartnerPatient advocacy partnership advocating for people with sleep apnea and providing comprehensive educational resources on sleep apnea and treatment options.
  • National Sleep Foundation (NSF)minorGTM or Marketing PartnerPatient advocacy partnership dedicated to improving health and well-being through sleep education and advocacy.
  • Project SleepminorGTM or Marketing PartnerPatient advocacy partnership dedicated to educating the public about sleep health, sleep equity, and sleep disorders through campaigns, events, and programs including the Sleep Apnea Squad educational series.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Apnimed competitors and assessment

Company assessment

Broad incumbents

  • ResMed: Global leader in CPAP and other OSA treatment devices; the dominant incumbent in obstructive sleep apnea therapy that Apnimed's AD109 oral pill would directly compete against by offering an alternative to PAP therapy.
  • Koninklijke Philips (Philips Respironics): Major CPAP and sleep-respiratory device manufacturer through its Respironics business, and Apnimed's CMO John Cronin was formerly Philips Respironics' Chief Medical Officer. A primary entrenched competitor in OSA treatment that AD109 would seek to displace.
  • Fisher & Paykel Healthcare: Major CPAP and nasal-interface manufacturer for OSA therapy; a broad incumbent in sleep apnea treatment whose device-based standard of care AD109 would seek to disrupt.
  • Eisai: Large Japanese pharma with sleep medicine franchise including Dayvigo (lemborexant) for insomnia; comparable as a broader pharma incumbent operating in the sleep medicine prescriber space.
  • Takeda Pharmaceutical: Global pharma with historical sleep/neurology franchises; comparable as a broad incumbent that has commercialized sleep-disorder therapies and competes for prescriber attention in sleep medicine.

Direct peers

  • Inspire Medical Systems: Developer of an FDA-approved implantable hypoglossal nerve stimulation system for OSA, directly competing with AD109 as an alternative to CPAP for patients who fail or refuse PAP therapy.
  • Shionogi & Co. Japanese pharma company that now fully owns the SASS joint venture and is developing sulthiame, an oral carbonic anhydrase inhibitor for OSA; a direct competitor in oral OSA pharmacotherapy and Apnimed's former JV partner.

Emerging players

  • Jazz Pharmaceuticals: Specialty pharma focused on sleep and neurological disorders with franchises in narcolepsy (Xywav, Sunosi); comparable as a sleep-disorder-focused commercial-stage pharma peer targeting similar prescriber channels.
  • Avadel Pharmaceuticals: Sleep-disorder pharma with Lumryz (once-at-bedtime sodium oxybate) for narcolepsy; comparable as a recent commercial-stage sleep pharma peer navigating payer access and prescriber adoption in sleep medicine.
  • Nyxoah: Developer of the Genio hypoglossal nerve stimulation system for OSA, an alternative-to-CPAP therapy that competes for the same patient population AD109 is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Apnimed social profiles

Digital presence

Apnimed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apnimed leadership team

Management profile

Number of profiles

Profiles12 records

Apnimed subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Apnimed funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apnimed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apnimed

What does Apnimed do?

Apnimed is a clinical-stage pharmaceutical company developing novel oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep-related breathing diseases. Its lead product candidate AD109 is a first-in-class fixed-dose combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor) administered as a once-daily bedtime pill. The drug targets the underlying neuromuscular dysfunction in OSA to improve upper airway muscle activity and maintain airway patency during sleep, representing what the company positions as a potential first oral pharmacological treatment for OSA.

Is Apnimed a public or private company?

Apnimed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Apnimed founded?

Apnimed was founded in 2017. It employs 51 to 100 people.

Where is Apnimed based?

Apnimed is headquartered in Cambridge, United States, in the North America region.

How does Apnimed make money?

One revenue line is on record: pharmaceutical product sales.

Who are Apnimed's main competitors?

Broad incumbents on record are ResMed, Koninklijke Philips (Philips Respironics), Fisher & Paykel Healthcare, Eisai and Takeda Pharmaceutical. Direct peers are Inspire Medical Systems and Shionogi & Co.. Emerging players are Jazz Pharmaceuticals, Avadel Pharmaceuticals and Nyxoah.

Does Apnimed have an API?

No public API is recorded for Apnimed.

What industry is Apnimed in?

Apnimed's product category is Sleep Apnea Therapeutics. Its primary akta.pro industry code is HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV), with a secondary code of HLAIADAG, Sleep, Stress & Mood Support. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeAPNIMED ($APMD) Releases Q3 2026 Earnings, Stock Rises | APMD Stock NewsAPNIMED reported Q3 2026 earnings of -$0.99 per share, missing estimates of -$0.62 by $0.37, with revenue of $0. The stock rose 1.44% after market open. Insiders made two purchases, and 51 institutional investors added shares, with a median price target of $50.HrtodayApnimed Appoints Allison Hernandez as Vice President, Human Resources Operations & Talent AcquisitionApnimed appointed Allison Hernandez as Vice President of Human Resources Operations and Talent Acquisition, bringing over 20 years of HR leadership experience. She previously served as Senior Director of HR at Kura Oncology and held roles at Catalent Pharma Solutions and Wawanesa Insurance. Apnimed is developing AD109, an oral treatment for obstructive sleep apnea.Business & FinancialApnimed, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Apnimed, Inc. reported inducement grants under Nasdaq Listing Rule 5635(c)(4) to employees entering employment, granted pursuant to a plan adopted by its board on August 21, 2026. The company is advancing its product candidate AD109, designed to improve oxygenation in individuals with obstructive sleep apnea.American Banking and Market NewsApnimed, Inc. (NASDAQ:APMD) Stock Rated “Moderate Buy” by Sell-Side AnalystsApnimed shares received a consensus "Moderate Buy" rating from five analysts, with an average 12-month target of $50.33. The company reported Q2 EPS of $0.51 on revenue of $12.08 million, and major shareholder Morningside Venture Investment bought 312,500 shares at $16.00 each.MarketBeatApnimed, Inc. (NASDAQ:APMD) Stock Rated "Moderate Buy" by Sell-Side AnalystsApnimed received a consensus 'Moderate Buy' rating from five analysts, with an average price target of $50.33. Major shareholder Morningside Venture Investment bought 312,500 shares at $16.00, increasing its stake by 4.57%. The stock traded at $17.76, down $0.49, with a market cap of $739.35 million.MarketBeatApnimed, Inc. (NASDAQ:APMD) Shares Shorted: Short Interest Up 100.6% in SeptemberApnimed's short interest rose 100.6% to 1,764,739 shares as of September 30, with 4.2% of shares sold short. The company reported Q2 EPS of $0.51 on revenue of $12.08 million, and analysts have a consensus price target of $50.33.GlobeNewswireApnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026Apnimed announced five abstracts accepted for CHEST 2026, including two late-breaking presentations on its AD109 drug for obstructive sleep apnea. The abstracts feature Phase 3 data and real-world studies, with a panel on SynAIRgy and LunAIRo trials. AD109's NDA is under FDA review with a PDUFA goal of February 28, 2027.Markets DailyApnimed, Inc. (NASDAQ:APMD) Shares Shorted: Short Interest Up 55.7% in SeptemberShort interest in Apnimed rose 55.7% to 879,684 shares as of September 15th. Major shareholder Morningside Venture Investment bought 312,500 shares at $16.00 each, increasing its stake by 4.57%. Analysts rate the stock a Moderate Buy with an average target of $50.33.Ticker ReportApnimed, Inc. (NASDAQ:APMD) Stock Has Consensus Price Target of $50.33 According to AnalystsApnimed's stock has a consensus price target of $50.33 from five brokerages, with four buy ratings and one hold. Major shareholder Morningside Venture Investment bought 312,500 shares at $16.00, increasing its stake by 4.57%. The company reported Q2 EPS of $0.51 on revenue of $12.08 million.Defense WorldApnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by BrokeragesApnimed shares received a consensus "Moderate Buy" rating from five brokerages, with an average target price of $50.33. The company reported Q2 EPS of $0.51 on revenue of $12.08 million, and major shareholder Morningside Venture Investment bought 312,500 shares at $16.00 each.